home

Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen™ for the evaluation of AGHD

TrendAeterna Zentaris 2015-11-20 15:50 Read   414

Aeterna Zentaris Inc.announced today that the first patient has been enrolled for the Company's confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD").

PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis

TrendPTC 2015-11-20 14:59 Read   361

PTC Therapeutics, Inc. today announced that it has completed enrollment of ACT CF, the company's second Phase 3 clinical trial of Translarna™ (ataluren) for patients with nonsense mutation cystic fibrosis (nmCF).

Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma

TrendTeva2015-11-20 14:25 Read   352

Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo .Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform.

Mallinckrodt boosts buyback plan amid news of a 2,000% price hike on infant drug

EVENTSMallinckrodt2015-11-20 13:06 Read   679

Mallinckrodt's shares have suffered since short seller Citron Research called out the company's pricing policies and marketing efforts last week.

Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial

EVENTSMerck2015-11-20 11:00 Read   289

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA and Merck's KEYTRUDA in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

Dermira Completes Patient Enrollment for Second CIMZIA(R) (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program

TrendDermira2015-11-20 10:18 Read   391

Enrollment Continues for Third and Final CIMZIA Phase 3 Trial in Patients With Moderate-to-Severe Plaque Psoriasis

Radius puts off its FDA filing to be 'respectful' of holiday plans

EVENTSBloomberg story2015-11-19 17:17 Read   236

Radius Health's shares slipped on Tuesday after the company said it was postponing a planned FDA filing for its osteoporosis drug.

Warburg puts up $300M to launch a buyout-hungry drug firm

EVENTSWarburg2015-11-19 16:37 Read   189

Private equity giant Warburg Pincus is diving into specialty pharmaceuticals, launching Vertice Pharma and promising to invest up to $300 million in the company as it scouts for buyable assets.

BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors

TrendBIND2015-11-19 15:55 Read   317

Dosing begins in phase 1 study of Aurora B kinase inhibitor nanomedicine developed in collaboration with AstraZeneca .BIND earns $4.0 million clinical milestone

Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

TrendPfizer2015-11-19 11:26 Read   674

Breakthrough Therapy designation highlights the potential of avelumab* as a new immunotherapy for patients with metastatic Merkel cell carcinoma (MCC).Metastatic MCC is a devastating disease and if approved, avelumab could potentially become the first immunotherapy to treat metastatic MCC.

Pharma faces 'challenging and prolonged' reforms in China, with pricing power at risk

EVENTS Reuters2015-11-18 17:37 Read   180

Big Pharma has already seen sales in China slow, thanks in part to stepped-up competition from local drugmakers. Healthcare reform there is also taking its toll.

Activist investor's new advice for Amgen: Merge with Allergan

EVENTSAmgen2015-11-18 16:48 Read   161

Dan Loeb, the activist investor who once called for Amgen ($AMGN) to break itself in two, is now advising the Big Biotech to consider merging with Allergan ($AGN), according to Bloomberg.